+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968594
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Non-small Cell Lung Cancer Therapeutics Market is projected to reach USD 38.26 Billion in 2026. It is expected to continue growing at a CAGR of 9.75%, reaching USD 67.13 Billion by 2032.

Non-small cell lung cancer (NSCLC) therapeutics are moving from broadly applied chemotherapy toward biomarker-led, stage-specific, and increasingly individualized treatment strategies. NSCLC accounts for approximately 80% to 85% of lung cancer cases, and lung cancer remains the leading cause of cancer death globally, with the International Agency for Research on Cancer estimating about 2.5 million new lung cancer cases and 1.8 million deaths in 2022.

The market is shaped by the clinical value of immune checkpoint inhibitors, targeted therapies for actionable alterations, antibody-drug conjugates, and perioperative regimens that extend systemic treatment into earlier-stage disease. As testing for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, HER2, and KRAS alterations becomes central to treatment selection, pharmaceutical, diagnostic, and provider ecosystems are increasingly linked through precision oncology workflows.

Transformative Shifts in the NSCLC Treatment Landscape

The NSCLC treatment landscape is undergoing structural change as immunotherapy and targeted therapy redefine standards of care across metastatic, adjuvant, and neoadjuvant settings. PD-1, PD-L1, and CTLA-4 pathway inhibitors have expanded survival-oriented treatment options, while targeted agents have produced clinically meaningful outcomes in biomarker-defined populations such as EGFR-mutated, ALK-positive, ROS1-positive, RET-positive, MET exon 14, BRAF V600E, NTRK fusion, HER2-altered, and KRAS G12C NSCLC.

A major transformation is the shift from single-line treatment thinking to lifecycle-based disease management. Molecular testing at diagnosis, minimal residual disease assessment, liquid biopsy adoption, and resistance-mechanism profiling are supporting more adaptive therapy selection. Regulatory approvals in resectable NSCLC have also changed commercial strategy by increasing focus on earlier intervention, multidisciplinary care coordination, and evidence generation beyond late-stage disease.

Cumulative Impact of Artificial Intelligence on NSCLC Therapeutics

Artificial intelligence is becoming an enabling layer across NSCLC therapeutics rather than a standalone replacement for clinical expertise. AI-supported radiology, pathology image analysis, trial-matching tools, and real-world evidence platforms can accelerate patient identification, improve operational efficiency, and support more consistent interpretation of complex clinical and molecular data.

The cumulative impact is most visible in precision oncology execution. AI can help identify suspicious lung nodules from imaging, prioritize cases for review, extract unstructured electronic health record data, and match patients to biomarker-driven trials. In drug development, machine learning is being applied to target discovery, synthetic control arms, pharmacovigilance signal detection, and patient stratification; however, clinical adoption depends on validation, regulatory oversight, data quality, interoperability, and protection against algorithmic bias.

Key Regional Insights Across Global NSCLC Therapeutics

In North America, NSCLC therapeutics benefit from advanced oncology infrastructure, broad access to next-generation sequencing, high clinical trial density, and rapid uptake of approved immunotherapies and targeted agents. The United States remains a global anchor for biomarker-driven drug development, while Canada’s public reimbursement environment emphasizes health technology assessment, real-world value, and equitable access across provinces.

Europe demonstrates strong adoption of guideline-based care through national health systems, cancer networks, and European regulatory pathways, although reimbursement timing differs by country. Asia-Pacific is highly consequential because of disease burden and distinct molecular epidemiology, particularly the higher prevalence of EGFR-mutated NSCLC reported in many East Asian populations compared with Western populations. China, Japan, South Korea, Australia, and India are expanding precision oncology capacity, trial participation, and domestic innovation.

Latin America shows growing demand for immuno-oncology and molecular diagnostics, but access is uneven due to reimbursement gaps and laboratory infrastructure differences. The Middle East, led by Gulf markets, is investing in oncology centers, genomic medicine programs, and specialty care capacity. Africa remains underpenetrated for advanced NSCLC therapeutics, with priorities centered on earlier diagnosis, pathology capacity, access to essential cancer medicines, and scalable diagnostic partnerships.

Key Group Insights for NSCLC Therapeutics

Within ASEAN, NSCLC therapeutics demand is shaped by rising cancer care investment, expanding private oncology networks, and uneven access to comprehensive genomic profiling across countries. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines present different reimbursement and infrastructure profiles, making partnership models and diagnostic affordability central to market development.

The GCC is advancing oncology through national transformation programs, specialized cancer centers, and investments in genomic medicine, supporting faster adoption of premium immunotherapies and targeted treatments in selected markets. The European Union provides a large, regulated environment where centralized authorization, health technology assessment reform, and cross-border clinical research influence access and evidence expectations. BRICS countries represent a major volume and innovation opportunity, especially as China, India, and Brazil expand local manufacturing, clinical trials, and precision oncology pathways.

G7 markets set many global benchmarks for clinical evidence, reimbursement negotiation, pharmacovigilance, and guideline adoption. NATO member countries overlap substantially with advanced Western oncology markets, where security of pharmaceutical supply chains, clinical research resilience, and health system readiness have become strategic considerations for high-value oncology therapeutics.

Key Country Insights in NSCLC Therapeutics

The United States leads NSCLC therapeutic innovation through regulatory approvals, high biomarker testing penetration in major cancer centers, and extensive clinical trial networks. Canada emphasizes evidence-based reimbursement and provincial access pathways, while Mexico and Brazil are expanding oncology capabilities but continue to face access variability between public and private systems.

In Europe, the United Kingdom relies on health technology assessments and national care pathways, Germany supports early access after European approval while benefit assessment shapes pricing, and France maintains strong oncology networks and reimbursement evaluation. Italy and Spain show broad specialist expertise with regional access differences, while Russia’s NSCLC environment is affected by domestic policy, procurement dynamics, and constrained access to some global innovations.

China is one of the most important NSCLC countries due to patient volume, high clinical trial activity, domestic biopharmaceutical development, and expanding reimbursement coverage for selected innovative drugs. India combines a large disease burden with affordability constraints and growing molecular diagnostics adoption. Japan and South Korea are advanced precision oncology markets with strong uptake of targeted therapies, while Australia benefits from structured reimbursement, national cancer strategies, and high-quality oncology care infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker access as a commercial and clinical imperative. Investments in companion diagnostics, reflex testing, liquid biopsy availability, and partnerships with pathology networks can reduce treatment delays and improve eligible patient identification for targeted therapies and immuno-oncology regimens.

Organizations should also design evidence strategies that address payer scrutiny across overall survival, progression-free survival, quality of life, treatment sequencing, and real-world effectiveness. Differentiation will increasingly depend on performance in defined subpopulations, tolerability, convenience, central nervous system activity, and resistance management.

Actionable priorities include expanding trial diversity, building region-specific access models, strengthening pharmacovigilance, integrating AI-enabled patient-finding tools responsibly, and preparing for combination therapy economics. Leaders that align therapeutic innovation with diagnostic readiness and reimbursement evidence will be better positioned in the evolving NSCLC therapeutics market.

Research Methodology for NSCLC Therapeutics Analysis

This executive summary is developed through a secondary research-led methodology using publicly available, verifiable sources, including regulatory agency communications, oncology guidelines, peer-reviewed literature, cancer registry data, clinical trial databases, and global health statistics. Emphasis is placed on validated epidemiology, approved therapeutic classes, established biomarkers, and documented regional access patterns.

Insights are synthesized through triangulation across clinical, regulatory, commercial, and healthcare-delivery evidence. The methodology prioritizes data integrity, avoids unsupported market claims, and distinguishes established clinical adoption from emerging opportunities. Where regional or country trends vary, interpretation is grounded in observable healthcare infrastructure, reimbursement systems, diagnostic capacity, and clinical research activity.

Conclusion: The Future of NSCLC Therapeutics

The NSCLC therapeutics market is entering a more sophisticated phase defined by precision medicine, immunotherapy integration, earlier-stage intervention, and AI-enabled care pathways. Scientific progress has expanded treatment options, but outcomes increasingly depend on timely diagnosis, comprehensive biomarker testing, therapy sequencing, and equitable access.

Organizations that connect drug development with diagnostics, real-world evidence, regional reimbursement strategies, and responsible digital innovation will be best positioned to create durable value. As NSCLC care continues to evolve, the most competitive stakeholders will be those that improve both therapeutic efficacy and the practical delivery of precision oncology at scale.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Non-small Cell Lung Cancer Therapeutics Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.3. Immunotherapy
7.3.1. CTLA-4 Inhibitors
7.3.2. PD-1 Inhibitors
7.3.2.1. Nivolumab
7.3.2.2. Pembrolizumab
7.3.3. PD-L1 Inhibitors
7.3.3.1. Atezolizumab
7.3.3.2. Avelumab
7.3.3.3. Durvalumab
7.4. Targeted Therapy
7.4.1. ALK Inhibitors
7.4.2. BRAF Inhibitors
7.4.3. EGFR Inhibitors
7.4.4. ROS1 Inhibitors
8. Non-small Cell Lung Cancer Therapeutics Market, by Line Of Therapy
8.1. Introduction
8.2. First Line
8.2.1. Chemotherapy
8.2.2. Combination Therapy
8.2.3. Immunotherapy
8.2.4. Targeted Therapy
8.3. Second Line
8.3.1. Chemotherapy
8.3.2. Combination Therapy
8.3.3. Immunotherapy
8.3.4. Targeted Therapy
8.4. Third Or Later
8.4.1. Chemotherapy
8.4.2. Combination Therapy
8.4.3. Immunotherapy
8.4.4. Targeted Therapy
9. Non-small Cell Lung Cancer Therapeutics Market, by Biomarker Expression
9.1. Introduction
9.2. ALK Rearrangement
9.3. EGFR Mutant
9.4. High PD-L1 Expression
9.5. KRAS Mutant
10. Non-small Cell Lung Cancer Therapeutics Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Oncology Clinics
10.4. Ambulatory Surgical Centers
10.5. Specialty Cancer Centers
11. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Non-small Cell Lung Cancer Therapeutics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Non-small Cell Lung Cancer Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Non-small Cell Lung Cancer Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Akeso, Inc.
16.3. Amgen Inc.
16.4. Astellas Pharma Inc.
16.5. AstraZeneca PLC
16.6. Bayer AG
16.7. BeiGene, Ltd.
16.8. Blueprint Medicines Corporation
16.9. Boehringer Ingelheim International GmbH
16.10. Bristol-Myers Squibb Company
16.11. Cullinan Therapeutics, Inc.
16.12. Daiichi Sankyo Company, Limited
16.13. Eisai Co., Ltd.
16.14. Eli Lilly and Company
16.15. Exelixis, Inc.
16.16. F. Hoffmann-La Roche Ltd.
16.17. Gilead Sciences, Inc.
16.18. GSK plc
16.19. Incyte Corporation
16.20. Innovent Biologics, Inc.
16.21. Johnson & Johnson
16.22. Merck & Co., Inc.
16.23. Novartis AG
16.24. Novocure GmbH
16.25. Pfizer Inc.
16.26. Regeneron Pharmaceuticals, Inc.
16.27. Sanofi S.A.
16.28. Summit Therapeutics Inc.
16.29. Takeda Pharmaceutical Company Limited
16.30. Zai Lab Limited
List of Figures
FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL NIVOLUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL NIVOLUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL NIVOLUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ATEZOLIZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ATEZOLIZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ATEZOLIZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL AVELUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL AVELUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL AVELUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL DURVALUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL DURVALUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL DURVALUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ALK INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ALK INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ALK INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL EGFR INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL EGFR INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL EGFR INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL THIRD OR LATER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL THIRD OR LATER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL THIRD OR LATER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ALK REARRANGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL ALK REARRANGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL ALK REARRANGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL EGFR MUTANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL EGFR MUTANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL EGFR MUTANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HIGH PD-L1 EXPRESSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL HIGH PD-L1 EXPRESSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HIGH PD-L1 EXPRESSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL KRAS MUTANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL KRAS MUTANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL KRAS MUTANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 171. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 172. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 173. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 174. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 175. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 176. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 177. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 178. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 179. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 180. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 181. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 182. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 198. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 199. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 200. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 201. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 202. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 203. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 204. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 205. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 206. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 207. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 208. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 210. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 212. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 213. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 214. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 215. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 216. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 217. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 218. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 219. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 220. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 221. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 222. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 224. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 225. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 226. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 227. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 228. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 229. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 230. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 231. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 232. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 233. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 234. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 235. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 250. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 252. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 253. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 254. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 255. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 256. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 257. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 258. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 259. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 260. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 261. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 265. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 266. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 267. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 268. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 269. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 270. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 271. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 272. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 273. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 274. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 275. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 277. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 278. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 279. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 280. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 281. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 282. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 283. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 284. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 285. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 286. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 287. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 289. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 303. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 305. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 306. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 307. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 308. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 309. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 310. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2017-2032 (USD MILLION)
TABLE 311. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2017-2032 (USD MILLION)
TABLE 312. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2017-2032 (USD MILLION)
TABLE 313. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2017-2032 (USD MILLION)
TABLE 314. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 315. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 316. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 317. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 318. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 319. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 320. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2017-2032 (USD MILLION)
TABLE 321. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 322. MEXICO NON-SMALL CELL LUNG CANCER THER

Companies Mentioned

  • AbbVie Inc.
  • Akeso, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cullinan Therapeutics, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GSK plc
  • Incyte Corporation
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Summit Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • Zai Lab Limited

Table Information

Report AttributeDetails
No. of Pages186
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 38.26 Billion
Forecasted Market Value ( USD ) by 2032 $ 67.13 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report - Product Image

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Non-Small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 981 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Non-Small Cell Lung Cancer (NSCLC) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 185 Pages
  • Global
From
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026 - Product Image

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 186 Pages
  • Global
From

About the Non Small Cell Lung Cancer Drug Market

The Non Small Cell Lung Cancer Drug market is a subset of the larger Lung Cancer Drug market. Non Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. NSCLC is typically treated with chemotherapy, radiation, and targeted therapies. Targeted therapies are drugs that target specific molecules involved in the growth and spread of cancer cells. These drugs are designed to block the growth and spread of cancer cells while limiting damage to healthy cells. The Non Small Cell Lung Cancer Drug market is highly competitive, with a number of companies offering various treatments. Companies such as AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer are some of the major players in the market. Other companies such as Amgen, Boehringer Ingelheim, and Novartis are also active in the market. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.